LNP

• Net Sales of €895 MM represented year-on-year growth of 4%, driven by strong performance of the European Dermatology business.
• Powered by our dedicated investments in launches and innovation, we achieved a 4% year-on-year growth in Net Sales, accounting for €895 MM, which was mainly driven by our European dermatology business.
• Almirall has complemented its exciting pipeline and discovery efforts through strategic partnerships, adding long-term value to its medical dermatology portfolio.
• The strategic focus on medical dermatology has positioned the company well for sustained growth and leadership in the medium term and beyond.

• Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, and ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis (CF).
• Intellia will be responsible for the design of the editing strategy and research-grade components for the investigational therapies.
• “This collaboration provides further validation of ReCode's SORT LNP platform to deliver diverse gene editing modalities to specific cells and tissues.
• By combining our highly synergistic technologies and capabilities, we are excited about the potential to enable a faster path for next-generation gene editing therapeutics to CF patients.”

• A national Newspoll, conducted January 31 to February 3 from a sample of 1,245, gave Labor a 52–48 lead, unchanged since the previous Newspoll in mid-December.
• Primary votes were 36% Coalition (steady), 34% Labor (up one), 12% Greens (down one), 7% One Nation (steady) and 11% for all Others (steady).
• Anthony Albanese’s net approval dropped one point to -9, while Peter Dutton’s net approval was down four points to -13.
• His net approval is still well below zero, and hasn’t recovered to its level before the Voice referendum defeat.

Essential poll: 48–46 to Labor

• In last week’s federal Essential poll, conducted January 24–28 from a sample of 1,201, Labor led by 48–46 including undecided (49–46 in December).
• Labor has led by one-to-three points in all Essential polls since late October.
• Primary votes were 34% Coalition (steady), 32% Labor (up one), 13% Greens (steady), 7% One Nation (up one), 2% UAP (steady), 7% for all Others (down two) and 5% undecided (steady).
• Analyst Kevin Bonham said Labor would have about a 53–47 lead in this poll by 2022 election preference flows.

Morgan poll and a second Queensland byelection

• In last week’s federal Morgan poll, conducted January 22–28 from a sample of 1,688, Labor led by 50.5–49.5, a two-point gain for the Coalition since the previous week.
• Primary votes were 37.5% Coalition (up 1.5), 31% Labor (down 1.5), 13% Greens (up 0.5), 5.5% One Nation (up 0.5) and 13% for all Others (down one).
• I covered the March 16 Queensland state byelection in Inala last fortnight.
• A second Queensland byelection will also occur on March 16 after Ipswich West’s Labor member Jim Madden resigned to contest the Ipswich local government elections on March 16.

Biden wins 96% in South Carolina Democratic primary

• At Saturday’s United States Democratic presidential primary in South Carolina, Joe Biden won 96.2% of the vote, Marianne Williamson 2.1% and Dean Phillips 1.7%.
• This result makes it all but certain that Biden will be the Democratic presidential nominee.
• In the Republican presidential contest, Donald Trump leads Nikki Haley nationally by 73.6–17.2 in the FiveThirtyEight aggregate.
• The next important contest is the February 24 Republican primary in South Carolina, Haley’s home state.

Adrian Beaumont does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

• CHENGDU, China, Jan. 24, 2024 /PRNewswire/ -- Kicking off the New Year with remarkable achievements, Chengdu-based WestGene made a significant impact at the 3rd mRNA-Based Therapeutics Summit in Berlin, Germany.
• The Summit, held January 23-25, is a key event in the field of mRNA drug development, attracting over 200 specialists from various parts of the world.
• Founded by two visionary scientists, Dr. Wei Yuquan and Dr. Xiangrong Song, WestGene Biotech is dedicated to pioneering the field of mRNA therapeutics.
• This project, along with its extensive pipeline, positions WestGene at the forefront of biopharmaceutical innovation and research.